ulipristal (ella) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ulipristal acetate (also known as CDB-2914 and PGL4001 and trade name Ella in the U.S) is a novel oral emergency contraceptive designed and developed by HRA Pharma. It is a selective progesterone receptor modulator, which reversibly blocks the progesterone receptors in target tissues it was approved in May 2009 by the European Commission and in August 2010 by the FDA as safe and effective in preventing unintended pregnancy for up to 120 hours – or five days – post- unprotected intercourse or contraceptive failure. Ella is not intended for routine use as a contraceptive. When taken immediately before ovulation is to occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy. The most common side effects are: headache, nausea, stomach (abdominal) pain, menstrual pain. Some women taking ella may have their next period earlier or later than expected. If your period is more than a week late, you should get a pregnancy test.   NCATS

Chemistry

  • SMILES: CN(C)C1=CC=C(C=C1)[C@H]2C[C@@]3(C)[C@@H](CC[C@]3(O)C(C)=O)[C@@H]4CCC5=CC(=O)CCC5=C24
  • InChIKey: HKDLNTKNLJPAIY-WKWWZUSTSA-N
  • Mol. Mass: 433.5824
  • ALogP: 4.97
  • ChEMBL Molecules:
    ulipristal  
    ulipristal acetate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$11.5100 - $34.2750
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

17alpha-acetoxy-11beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione | cdb 2914 | cdb-2914 | ella | ella norpregnadiene | ellaone | esmya | hrp 2000 | hrp-2000 | rti-3021-012 | rti-3021-022 | ulipristal | ulipristal acet | ulipristal acetate | va2914 | va-2914

Organizations (50)

Research & Development (49)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (33)

Approved Indications (1)


 

Pregnancy (approved 2010)

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Abortion, Induced (Phase 4)

Abortion, Missed (Phase 2)

Abortion, Spontaneous (Phase 2)

Adenomyosis (Phase 4)

Breast Neoplasms (Phase 2)

Charcot-Marie-Tooth Disease (Phase 2)

Contraception (Phase 4)

Contraception Behavior (Phase 4)

Contraception, Postcoital (Phase 4)

Contraceptive Agents (Phase 2)

Depression (Phase 2)

Dysmenorrhea (Phase 4)

Endometriosis (Phase 4)

Fertilization in Vitro (Phase 4)

Fibroins (Phase 3)

Genital Diseases, Female (Phase 2)

Healthy Volunteers (Phase 2)

Hemorrhage (Phase 4)

Infertility (Phase 4)

Kidney Diseases (Phase 1)

Leiomyoma (Phase 4)

Menorrhagia (Phase 4)

Obesity (Phase 4)

Ovulation Inhibition (Phase 1/Phase 2)

Postmenopause (Phase 2)

Pregnancy Complications (Phase 2)

Premenstrual Dysphoric Disorder (Phase 2)

Premenstrual Syndrome (Phase 2)

Prostheses and Implants (Phase 4)

Urogenital Abnormalities (Early Phase 1)

Uterine Diseases (Phase 4)

Uterine Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial Organizations: 49

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue